NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries GlobeNewswire October 29, 2025 NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise in […]